Stock Market News 16 October 2025

Stock Rally and Analyst Buzz PLUG’s October rally caught Wall Street’s eye. After slipping for much of 2025, the stock surged in early October as analysts turned bullish and hydrogen demand news broke. For example, H.C. Wainwright on Oct. 3 raised PLUG’s price target from $3 to $7 and maintained a Buy ratingmarketbeat.com, and HSBC upgraded Plug to a “Strong Buy” on Oct. 9marketbeat.com. These upbeat calls came as the company announced its first big electrolyzer delivery in Europe. The result: Plug’s shares nearly doubled since early September, trading around $4.05 by Oct. 14ts2.tech – near a 52-week high –

Stock Trends and Recent Moves Western Alliance’s stock has been volatile recently. After rallying through summer, it tumbled in early October. On Oct 8, WAL fell about 4% amid headlines that a Jefferies-managed fund (Point Bonita) held ~$715 million in First Brands receivablests2.techmlq.ai. By Oct 15, WAL closed near $78.84, down ~4% for the dayinvesting.com. Trading volume surged as investors digested the news. A day later (Oct 16), Reuters reported WAL shares were still down ~5.4%reuters.com, despite the bank’s reassurances. Management disclosed it had filed a fraud lawsuit related to one credit and said its “criticized assets” (weak loans) actually

Whitehawk’s stock popped dramatically on Oct. 16 after news of the Tempus collaboration. Shares had been around $2 per share in mid-Octoberstockinvest.us, but the new AI partnership sent them soaring in early trading. By mid-day Oct. 16, various data sites showed WHWK up roughly 50–67% on the sessioninvesting.com. (For comparison, it had already gained ~6.6% on Oct. 15stockinvest.usstocktitan.net.) The sudden jump reflects investor excitement about the Tempus deal, which was announced in a press release on Oct. 16marketscreener.com. The Tempus AI collaboration was officially billed as a “multi-year” partnership to use Tempus’s de-identified, multimodal clinical data to improve Whitehawk’s ADC

Recent Clinical Developments and Pipeline Updates Theriva Biologics – a Rockville, MD-based clinical-stage biotech – has made headlines with promising cancer trial results. On October 13, 2025, the company announced that expanded data from its VIRAGE Phase 2b trial in metastatic pancreatic ductal adenocarcinoma will be presented at the ESMO 2025 Congress on Oct. 20 ts2.tech. In this trial, patients receiving VCN-01 (an oncolytic adenovirus therapy) plus standard gemcitabine/nab-paclitaxel chemo showed markedly better outcomes than chemo alone. Interim data filed with the SEC reveal VCN-01 improved median overall survival to around 11–14 months versus ~8–11 months for chemo-only patients ts2.tech.

Axon Stock Sinks Despite Market Strength Axon shares suffered an unexpected jolt mid-week, falling over 8% in a single session – a steep one-day drop for a typically steady climber. The slide to $644.99 nasdaq.com on Wednesday came with no obvious bad news from the company. In fact, broader market conditions were positive: U.S. stocks rose on the same day on optimism about trade and interest rates ts2.tech. This made Axon’s decline stand out even more, as the stock vastly underperformed major indexes. Technical factors likely played a role. Axon’s plunge pushed it below its 200-day moving average (~$677) nasdaq.com,